More serious issues than the name change, page-9

Lawrence is Gonski. Share price on hs watch has fallen off a cliff. It was smashed if memory serves the day he was announced as Interim Chair. I kept an open mind until his lachlustre performance at the last AGM.
It was underwhelming as he fluffed his lines and struggled nervously to conduct the meeting.
Since then he has ripped the highest director fees from POH in its history and yet has overseen a year when POH failed to deliver on nearly every promised KPI. As a result I expect POH will receive its 1st strike when shareholders vote against Resolution 2 The Renumeration Report- which wont be a good look for POH and the board.
And more - Lawrence has failed to buy a single share in his year at the helm. What does this say to the investment community. As Founder and Chief Investment Officer of Scientia Capital he has been regailed as a Leading Fund Manager - one who clearly doesnt rate POH but is happy to recieve a couple of hundred large to sit on our board. Frankly Im disgusted by his performance and think of 2014 as a lost year for POH.

We now have some seriously talented new directors - I agree with GC - Lankou would be the obvious choice to Chair Poh. With his background as CEO of Endo Pharma hs appointment would signal to the investor and Pharma communties that. POH is to be taken seriously and has reset its commercial compass.

VOTE NO TO RESOLUTION 1A Election of Lawrence Gozlan.
WE can do so much better